MedPacto, Inc. (KOSDAQ:235980)
South Korea · Delayed Price · Currency is KRW 4,315.00
+75.00 (1.77%)
Jul 18, 2025, 3:30 PM KST
MedPacto Company Description
MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea.
The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors.
MedPacto, Inc. is based in Seoul, South Korea.
MedPacto, Inc.
| Country | South Korea |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 61 |
| CEO | Seong-Jin Kim |
Contact Details
Address: Borim Building Seoul, 06668 South Korea | |
| Phone | 82 2 6938 0200 |
| Website | medpacto.com |
Stock Details
| Ticker Symbol | 235980 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7235980000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Seong-Jin Kim | Chief Executive Officer |